An appeal can be lodged against the final draft guidance by any of the appraisal consultees within 15 days from the day the final draft guidance is issued.
The appeals process is managed by the corporate office at NICE to provide independence from the teams that develop the guidance.
Grounds of appeal
The grounds of appeal are:
Ground 1: In making the assessment that preceded the recommendation, NICE has:
a) failed to act fairly
b) exceeded its powers
Ground 2: The recommendation is unreasonable in the light of the evidence submitted to NICE.
The Appeal Panel can only consider appeals that fall within one or more of these grounds. Appeals on any other grounds will not be considered.
Either or both parts of ground 1 can be appealed. Appeals on any other grounds will not be considered.
Paddy Storrie, former lay chair of the appeal panel, explains the appeals process
Who makes up the appeal panel?
Appeal panels are drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
- Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
- Cabozantinib for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine [ID4046]
- Baricitinib for treating severe alopecia areata [ID3979]
- Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
- Molnupiravir, remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261]